Show simple item record

dc.contributor.authorJames, R
dc.contributor.authorGlynne-Jones, R
dc.contributor.authorMeadows, H
dc.contributor.authorCunningham, D
dc.contributor.authorMyint, A
dc.contributor.authorSaunders, Mark P
dc.contributor.authorMaughan, T
dc.contributor.authorMcDonald, A
dc.contributor.authorEssapen, S
dc.contributor.authorLeslie, M
dc.contributor.authorFalk, S
dc.contributor.authorWilson, C
dc.contributor.authorGollins, S
dc.contributor.authorBegum, R
dc.contributor.authorLedermann, J
dc.contributor.authorKadalayil, L
dc.contributor.authorSebag-Montefiore, D
dc.date.accessioned2013-07-08T15:05:22Z
dc.date.available2013-07-08T15:05:22Z
dc.date.issued2013-05
dc.identifier.citationMitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. 2013, 14 (6):516-24 Lancet Oncolen_GB
dc.identifier.issn1474-5488
dc.identifier.pmid23578724
dc.identifier.doi10.1016/S1470-2045(13)70086-X
dc.identifier.urihttp://hdl.handle.net/10541/295471
dc.description.abstractChemoradiation became the standard of care for anal cancer after the ACT I trial. However, only two-thirds of patients achieved local control, with 5-year survival of 50%; therefore, better treatments are needed. We investigated whether replacing mitomycin with cisplatin in chemoradiation improves response, and whether maintenance chemotherapy after chemoradiation improves survival.
dc.language.isoenen
dc.rightsArchived with thanks to The lancet oncologyen_GB
dc.titleMitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.en
dc.typeArticleen
dc.contributor.departmentThe Kent Cancer Centre, Maidstone, UK.en_GB
dc.identifier.journalThe Lancet Oncologyen_GB
html.description.abstractChemoradiation became the standard of care for anal cancer after the ACT I trial. However, only two-thirds of patients achieved local control, with 5-year survival of 50%; therefore, better treatments are needed. We investigated whether replacing mitomycin with cisplatin in chemoradiation improves response, and whether maintenance chemotherapy after chemoradiation improves survival.


Files in this item

This item appears in the following Collection(s)

Show simple item record